<?xml version="1.0" encoding="UTF-8"?>
<abstract id="mja250577-abs-0001">
 <title>Abstract</title>
 <sec id="mja250577-sec-0001">
  <title>Objectives</title>
  <p>To assess the efficacy of corticosteroid treatment of patients with coronavirus disease 2019 (
   <styled-content style="fixed-case" toggle="no">COVID</styled-content>‐19).
  </p>
 </sec>
 <sec id="mja250577-sec-0002">
  <title>Design, setting</title>
  <p>Observational study in the two 
   <styled-content style="fixed-case" toggle="no">COVID</styled-content>‐19‐designated hospitals in Wuhu, Anhui province, China, 24 January – 24 February 2020.
  </p>
 </sec>
 <sec id="mja250577-sec-0003">
  <title>Participants</title>
  <p>Thirty‐one patients infected with the severe acute respiratory coronavirus 2 (
   <styled-content style="fixed-case" toggle="no">SARS</styled-content>‐CoV‐2) treated at the two designated hospitals.
  </p>
 </sec>
 <sec id="mja250577-sec-0004">
  <title>Main outcome measures</title>
  <p>Virus clearance time, length of hospital stay, and duration of symptoms, by treatment type (including or not including corticosteroid therapy).</p>
 </sec>
 <sec id="mja250577-sec-0005">
  <title>Results</title>
  <p>Eleven of 31 patients with 
   <styled-content style="fixed-case" toggle="no">COVID</styled-content>‐19 received corticosteroid treatment. Cox proportional hazards regression analysis indicated no association between corticosteroid treatment and virus clearance time (hazard ratio [
   <styled-content style="fixed-case" toggle="no">HR</styled-content>], 1.26; 95% 
   <styled-content style="fixed-case" toggle="no">CI</styled-content>, 0.58–2.74), hospital length of stay (
   <styled-content style="fixed-case" toggle="no">HR</styled-content>, 0.77; 95% 
   <styled-content style="fixed-case" toggle="no">CI</styled-content>, 0.33–1.78), or duration of symptoms (
   <styled-content style="fixed-case" toggle="no">HR</styled-content>, 0.86; 95% 
   <styled-content style="fixed-case" toggle="no">CI</styled-content>, 0.40–1.83). Univariate analysis indicated that virus clearance was slower in two patients with chronic hepatitis B infections (mean difference, 10.6 days; 95% 
   <styled-content style="fixed-case" toggle="no">CI</styled-content>, 6.2–15.1 days).
  </p>
 </sec>
 <sec id="mja250577-sec-0006">
  <title>Conclusions</title>
  <p>Corticosteroids are widely used when treating patients with 
   <styled-content style="fixed-case" toggle="no">COVID</styled-content>‐19, but we found no association between therapy and outcomes in patients without acute respiratory distress syndrome. An existing 
   <styled-content style="fixed-case" toggle="no">HBV</styled-content> infection may delay 
   <styled-content style="fixed-case" toggle="no">SARS</styled-content>‐CoV‐2 clearance, and this association should be further investigated.
  </p>
 </sec>
</abstract>
